Failed in phase 2
Thioctic acid: slow disability worsening in secondary progressive MS
secondary progressive MS · Mitochondrial / oxidative stress
Controlled phase 2 trials did not meet their main goal for this group.
- Trials
- 2
- Running now
- 1
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 115
How the verdict was reached
Negative in phase 2
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| LAPMS | Phase 2 | 115 | 2018 | Missed its main goal | Counted |
| OCTOPUS | Phase 3 | 1,200 | 2023 | Still running | Not counted: not randomised |
Counted: 1. Will count later: 0. Not counted: 1.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as Failed in phase 2
Related hypotheses
- Acetylcysteine: protect nerve tissue in secondary progressive MS
- Metformin: protect nerve tissue in secondary progressive MS
- Biotin: slow disability worsening in secondary progressive MS
- Metformin: slow disability worsening in secondary progressive MS
- Thioctic acid: slow disability worsening in primary progressive MS
- Metformin: reduce relapses and new lesions in secondary progressive MS
Assembled by software from public sources.